What kind of medicine does Ixabepilone belong to? Indications analysis

Ixabepilone is an anti-tumor drug that belongs to the microtubule inhibitor class. It is derived from the structural modification of epipodophyllotoxin (epothilones) and is obtained through a semi-synthetic method. Its core mechanism of action is to bind to intracellular β-tubulin to promote the stability of microtubules, thereby blocking the dynamic depolymerization process of microtubules. Since microtubules are essential structures for cell division, ixabepilone can directly inhibit the mitosis of cancer cells, causing cells to stall in mid-mitosis, ultimately inducing apoptosis. It is similar to traditional paclitaxel drugs, but its molecular structure has been optimized, is more stable, and is less sensitive to common multidrug resistance mechanisms, so it can break through the limitations of partially drug-resistant tumors in clinical practice.

From the perspective of drug classification, ixabepilone can be classified as a "natural product-derived microtubule inhibitor" and also regarded as a "late-line chemotherapy drug." Its research and development goal is to fill the treatment gap after the failure of commonly used chemotherapy drugs such as anthracyclines and taxanes. Compared with traditional drugs, its biggest feature is that it is insensitive to drug resistance mediated by P-glycoprotein, so it can still exert a good effect in patients with taxane-resistant breast cancer.

In terms of indications, ixabepilone is mainly used to treat advanced or metastatic breast cancer. International clinical practice guidelines generally recommend ixabepilone as a rescue treatment option after failure of anthracycline and taxane therapy. Especially when combined with capecitabine (Capecitabine), it can improve the disease control rate and delay progression. Single-agent ixabepilone can also be used, but is often more suitable for patients who have received multiple lines of therapy and are physically fit. Its clinical value lies in providing new possibilities for patients who lack options, especially when tumors progress rapidly.

Reference materials:https://www.drugs.com/mtm/ixabepilone.html